Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal
Xiaoxin Hao(Baylor College of Medicine), Xiang H.-F. Zhang(Baylor College of Medicine), Yichao Shen(Baylor College of Medicine), Chih‐Yen Tu(National Chung Hsing University), Hilda L. Chan(Baylor College of Medicine), Po‐Ren Hsueh(China Medical University), Luis Becerra Dominguez(Baylor College of Medicine), Yang Gao(Baylor College of Medicine), Elizabeth Valverde(Baylor College of Medicine), Shu‐Hsia Chen(Houston Methodist), Bradley C. Pingel(Baylor College of Medicine), Yunfeng Ding(Baylor College of Medicine), Laura Natalee Michie(Baylor College of Medicine), Bora Lim(Baylor College of Medicine), Liqun Yu(Baylor College of Medicine), David G. Edwards(Baylor College of Medicine), Igor Bado(Tisch Hospital), Angela Alexander(The University of Texas MD Anderson Cancer Center), Liang‐Chih Liu(National Taipei University of Technology), Mien‐Chie Hung(Precision Therapeutics (United States)), Zhan Xu(Baylor College of Medicine), Naoto T. Ueno(Breast Cancer Care), Charlotte Helena Rivas(Baylor College of Medicine), Jun Liu(Tongji University), Weijie Zhang(Nanjing Medical University), Nan Chen(Shanghai Normal University), Ling Wu(Baylor College of Medicine), Sergio Aguirre(Baylor College of Medicine), Fengshuo Liu(Baylor College of Medicine), Yi-Hsuan Wu(Baylor College of Medicine)
Cited by 59
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
|Nature Communications|2016|1.1k